News

COPAN Diagnostics, Inc. will unveil “MilkyWay,” the first fully automated instrument for preparing pour plate total viable bacterial counts on liquid samples, at the International Association for Food Protection Annual Conference in Tampa, Florida today. The conference runs from July 9, 2017 through July 11, 2017. The “MilkyWay” instrument draws from COPAN’s extensive experience in automation and culture of innovation.

In this study, Rebbapragada et al examined FecalSwab’s compatibility with the Seegene’s molecular chemistry, and FecalSwab’s convenience and utility when used with an automated pipetting platform employed within the assay. The study showed FecalSwab’s improved limit of detection when compared to traditional enteric transport media.

A recent study set out to determine the most effective, rapid and least invasive method to collect stool samples and quickly treat patients suffering from gastrointestinal diseases.

Visit COPAN during the Molecular Med Tri-Conference in San Francisco, to discover more about Copan’s B2B molecular transport development capabilities and resources. The booth will feature eNat™, Copan’s successful DNA and RNA preservation system suitable for a variety of sample types including urine and respiratory disease diagnostics or Hospital Acquired Infections (HAI) surveillance testing

Alfalfa, cattle, leafy greens and rosy cheeked children share space in COPAN Diagnostic’s new environmental sampling film, which emphasizes the food industry’s shift from response to prevention. The video, released today, highlights how COPAN’s Swab Rinse Kit (SRK^®) is an efficient, convenient product that simplifies the surface sampling process in the wake of the new FDA Food Safety Modernization Act (FSMA).

A recent study conducted at Tampa General Hospital in Florida, and published in the Journal of Clinical Microbiology, tested the use of ESwab™ with the BD Max MRSAXT and BD Max StaphSR assays. The study, consisting of 255 samples collected using ESwab™ showed that the assays have exceptional sensitivity and specificity for detecting MRSA and S. aureus, respectively

This agreement allows bioMérieux to speed up deployment of its “FMLA^® Lab Efficiency*” vision for the automation and enhanced operational efficiency of clinical microbiology labs. In this field, the two companies also plan to collaborate in particular for the development of innovative clinical microbiology diagnostic solutions.

Colibri™ is an open platform capable of utilizing a diversity of consumables from different suppliers or prepared in house. In keeping with the philosophy of developing open platforms, Colibri™ can work in-line with WASPLab™ or as a standalone workstation to automatically prepare AST and ID suspensions and seed MALDI-TOF target plates with more functionality to come.